Rodman & Renshaw Reiterates Geron Market Outperform, $9 PT

Rodman & Renshaw reiterated its Geron GRN Market Outperform / Speculative Risk rating and $9 price target in a research report published today. In the report, Rodman & Renshaw states, "With the spinal cord injury trial enrolling, a broad Phase 2 program for Imetelstat underway, and partnerships with GE Healthcare and AngioChem, we believe Geron represents an attractive opportunity for the risk-oriented, long-term investor." Shares of Geron were trading at $3.60 at the time of posting, down 3.61% from Monday's market close.